Eli Lilly Drops After Verzenio Fails To Meet Primary Endpoint In Phase 3 Study
October 10, 2017 at 14:18 PM EDT
Shares of Eli Lilly dropped in morning trading after the large-cap drugmaker said its drug to treat non-small cell lung cancer failed to meet its primary goal in a clinical trial.
